Goldman Sachs’s AbCellera Biologics ABCL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $750K | Buy |
218,725
+132,242
| +153% | +$454K | ﹤0.01% | 4021 |
|
|
2025
Q1 | $193K | Sell |
86,483
-213,330
| -71% | -$476K | ﹤0.01% | 4688 |
|
|
2024
Q4 | $878K | Buy |
299,813
+94,106
| +46% | +$276K | ﹤0.01% | 3988 |
|
|
2024
Q3 | $535K | Buy |
205,707
+109,939
| +115% | +$286K | ﹤0.01% | 4082 |
|
|
2024
Q2 | $283K | Sell |
95,768
-110,659
| -54% | -$328K | ﹤0.01% | 4240 |
|
|
2024
Q1 | $935K | Sell |
206,427
-394,814
| -66% | -$1.79M | ﹤0.01% | 3661 |
|
|
2023
Q4 | $3.43M | Buy |
601,241
+341,945
| +132% | +$1.95M | ﹤0.01% | 2853 |
|
|
2023
Q3 | $1.19M | Sell |
259,296
-160,981
| -38% | -$741K | ﹤0.01% | 3425 |
|
|
2023
Q2 | $2.71M | Buy |
420,277
+68,931
| +20% | +$445K | ﹤0.01% | 3004 |
|
|
2023
Q1 | $2.65M | Sell |
351,346
-113,530
| -24% | -$856K | ﹤0.01% | 3014 |
|
|
2022
Q4 | $4.71M | Buy |
464,876
+63,659
| +16% | +$645K | ﹤0.01% | 2665 |
|
|
2022
Q3 | $3.97M | Buy |
401,217
+166,730
| +71% | +$1.65M | ﹤0.01% | 2824 |
|
|
2022
Q2 | $2.5M | Buy |
234,487
+121,762
| +108% | +$1.3M | ﹤0.01% | 3268 |
|
|
2022
Q1 | $1.1M | Sell |
112,725
-22,724
| -17% | -$222K | ﹤0.01% | 4032 |
|
|
2021
Q4 | $1.94M | Buy |
135,449
+116,704
| +623% | +$1.67M | ﹤0.01% | 3526 |
|
|
2021
Q3 | $376K | Sell |
18,745
-12,310
| -40% | -$247K | ﹤0.01% | 4533 |
|
|
2021
Q2 | $683K | Buy |
31,055
+3,323
| +12% | +$73.1K | ﹤0.01% | 4253 |
|
|
2021
Q1 | $942K | Buy |
+27,732
| New | +$942K | ﹤0.01% | 3955 |
|